Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hematologic Neoplasms × apalutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 41 Prostatic Neoplasms, Castration-Resistant 2 Neoplasm Metastasis 2 Stage II Prostate Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Prostate Cancer Metastatic Disease 1 Prostate Adenocarcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Low Risk Prostate Cancer 1 High Risk Prostate Cancer 1 Hematologic Neoplasms 1 Castration Levels of Testosterone 1 Carcinoma, Small Cell 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Cyclophosphamide 33 fludarabine 29 Tacrolimus 23 Whole-Body Irradiation 22 Mycophenolic Acid 21 Busulfan 20 fludarabine phosphate 18 Melphalan 16 thymoglobulin 14 Antilymphocyte Serum 14 Thiotepa 11 Methotrexate 11 Stem Cell Transplantation 8 Rituximab 7 Granulocyte Colony-Stimulating Factor 7 Sirolimus 6 Filgrastim 6 trametinib 5 ruxolitinib 4 merphos 4 Nivolumab 4 Cytarabine 4 Cyclosporine 4 Cord Blood Stem Cell Transplantation 4 fedratinib 3 ceritinib 3 Radiotherapy 3 Peripheral Blood Stem Cell Transplantation 3 Pentostatin 3 Mesna 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05159245 2024-07-15

FINPROVE

Helsinki University Central Hospital

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡